stockrowIDEAYA Biosciences, Inc.
IDYA Healthcare Biotechnology
IDEAYA Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $218.7 million, up 3,024.4% from fiscal 2024.
- Revenue
- −95.1%
- EPS
- −190.5%
- Free cash flow
- −165.9%
Quarter to September 2026, against a year earlier
Follow IDYA
Alert me
IDEAYA Biosciences, Inc. (IDYA) EBITDA
IDEAYA Biosciences, Inc.'s EBITDA for fiscal 2025 was −$164.7M, compared with −$346.4M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$463.5M. Over the past ten years it has ranged from −$346.4M (fiscal 2024) to −$14.1M (fiscal 2017); the current reading is higher than 22% of that period. IDEAYA Biosciences, Inc. ranks 573rd of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$164.7M | — |
| FY2024 | −$346.4M | — |
| FY2023 | −$142.0M | — |
| FY2022 | −$59.7M | — |
| FY2021 | −$46.7M | — |
| FY2020 | −$33.4M | — |
| FY2019 | −$43.5M | — |
| FY2018 | −$36.3M | — |
| FY2017 | −$14.1M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | −$137.8M | — |
| Jun 2026 | −$122.2M | — |
| Mar 2026 | −$108.6M | — |
| Dec 2025 | −$94.9M | — |
| 29 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| ELVN Enliven Therapeutics, Inc. compare | −$123.8M |
| CELC Celcuity, Inc. compare | −$204.0M |
| BEAM Beam Therapeutics Inc. compare | −$381.7M |
| IDYA IDEAYA Biosciences, Inc. | −$463.5M |
| VRDN Viridian Therapeutics, Inc. compare | −$474.6M |
| DNLI Denali Therapeutics Inc. compare | −$524.5M |
| DYN Dyne Therapeutics, Inc. compare | −$536.1M |
| TARS Tarsus Pharmaceuticals, Inc. compare | −$695.5M |
| TLX Telix Pharmaceuticals Limited compare | — |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on IDYA
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement